MetaCap

Immutep Limited ADR (IMMP)

NASDAQ: IMMPHealth CareBiotechnology: Pharmaceutical PreparationsUSD

3.11-0.31 (-9.06%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

IMMP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$22.92M
EPS (TTM)
-$7.30
52-week range
2.66 – 70.60
Day range
3.09 – 3.41
Volume / Avg
44.77K / 26.07K
Beta
—

52-week range

$2.66$70.60

IMMP stock today

Shares of Immutep (IMMP) finished lower on Nov 20 at $3.11, a drop of 9.06% or $0.31 per share, versus the S&P 500's 3.70% decline. Shares are 95.6% below their 52-week high of $70.60 and 16.9% above the 52-week low of $2.66, near the bottom of the past year's range. IMMP is up 8.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 80.8%.

Immutep has posted a net loss over the last twelve months (EPS of -$7.30), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Immutep

Company profile

Immutep Limited, a clinical-stage biotechnology company, develops lymphocyte activation gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases in Australia. The company's lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on the LAG-3 immune control mechanism for the treatment of cancer. Its product pipeline also includes AIPAC-003, which has completed an integrated Phase II/III clinical trial for the treatment of metastatic breast cancer; TACTI-003, which has completed a Phase IIb clinical trial to treat first line head and neck squamous cell carcinoma (1L HNSCC); an investigator-initiated Phase II trial evaluating neoadjuvant efti as monotherapy and in combination with chemotherapy prior to surgery in patients with early-stage HR+/HER2-negative breast cancer; and EFTISARC-NEO, which is in a Phase II clinical trial for the treatment of soft tissue sarcoma.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Mr. Marc Voigt
Headquarters
Sydney, NSW

Analyst forecast

Forecast

Consensus

none

Avg. price target

$30.00+864.63%

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

IMMP news

All IMMP news

Immutep peers

Health Care sector
IMMP peer companies
CompanyPrice% ChgMarket capCompare
RMTIRockwell Medical Inc.5.82-7.03%$23.12Mvs IMMP
IXHLIncannex Healthcare Inc.1.86+6.90%$23.34Mvs IMMP
ABVCABVC BioPharma Inc.0.8663-1.56%$23.37Mvs IMMP
SCYXSCYNEXIS Inc.2.38-8.64%$23.69Mvs IMMP
CRVOCervoMed Inc.1.46+9.77%$22.09Mvs IMMP
LITSLite Strategy Inc.0.8026-4.03%$23.99Mvs IMMP
AARDAardvark Therapeutics Inc.0.9226-7.74%$20.20Mvs IMMP
RNAZTransCode Therapeutics Inc.1.16-10.77%$20.07Mvs IMMP

Indexes, lists and sector

Immutep stock FAQ

What is Immutep's stock price today?

IMMP last traded at $3.11 as of Nov 20, 4:00 PM EST, down 9.06% on the day. Prices are delayed at least 15 minutes.

Does Immutep pay a dividend?

No. Immutep does not currently pay a regular cash dividend.

Who is Immutep's CEO?

Mr. Marc Voigt is the chief executive officer of Immutep Limited ADR.

Has IMMP ever split its stock?

Yes. The most recent IMMP stock split was a 1-for-20 split on Sep 28, 2026, one of 2 splits on record.

What is the IMMP 52-week high?

The 52-week high for IMMP is $70.60 and the 52-week low is $2.66. The stock is currently 95.6% below its high.

Compare IMMP